The generic availability of Qulipta (atogepant) is tied to the expiration of its relevant patents. As of now, there is no generic version of Qulipta available.
When Does Qulipta's Patent Protection End?
The primary patent protecting Qulipta is expected to expire in 2037. However, this date can be influenced by various factors, including potential patent challenges and the granting of additional exclusivities [1]. Information on specific patent expiry dates can be tracked on resources like DrugPatentWatch.com [1].
What Is Atogepant?
Atogepant, marketed as Qulipta, is an oral medication used for the preventive treatment of migraine [2]. It belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists [2].
How Does Atogepant Work?
Atogepant functions by blocking the action of CGRP, a molecule that plays a role in migraine pain [2]. By inhibiting CGRP, the medication helps to prevent migraine attacks from occurring [2].
What Are the Alternatives to Qulipta?
Besides atogepant, other CGRP pathway inhibitors are available for migraine prevention. These include injectable CGRP monoclonal antibodies (mAbs) such as erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti). Oral CGRP antagonists, like rimegepant (Nurtec ODT), are also available for both prevention and acute treatment of migraine [3].
Who Makes Qulipta?
Qulipta is manufactured by AbbVie [4].
What Are the Potential Risks of Atogepant?
While generally well-tolerated, potential side effects of atogepant can include upper respiratory tract infection, nausea, diarrhea, and fatigue [2]. It is important for patients to discuss any concerns with their healthcare provider.